Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism (VTE) in Patients with Cancer

Study Status

Closed to Enrollment

Study Description

The purpose of this study is to use the drug tinzaparin for primary treatment and secondary prophylaxis (prevention) of venous thromboembolism (a bloood clot that forms within a vein) in patients with cancer. 

All eligible subjects with venous thromboembolism (VTE) will receive tinzaparin 175 U/kg/day for at least 6 months, with another 6 months at the study doctor's discretion (up to one year study treatment). Plasma markers of hemostasis, fibrolysis, and angiogenesis will be measured at baseline and at 7 days, 1 month, and 6 months after start of tinzaparin treatment (if subject agrees).

Patients with cancer but without blood clots (control group) will also be enrolled in this study but will not receive study drug. For these patients, information regarding overall heath and response to their cancer treatment will be monitored. Plasma markers of hemostasis, fibrinolysis, and angiogenesis will be measured at baseline and at 7 days, 1 month, and 6 months (if subject agrees)

Disease Status and/or Stage

Any Stage of Cancer

Key Eligibility

VTE Treatment Group:

  • Age 18 or older
  • Diagnosed with active cancer
  • Have a documented first venous thromboembolic event
  • Currently receiving any treatment for cancer
  • Not in need of long-term anti-coagulation therpay
  • Not undergoing high dose chemotherapy for peripheral blood stem cell or bone marrow transplantation, induction chemotherapy for acute leukemia or have other conditions associated wtih persistent thrombocytopenia of less that 100x109/L for a duration of at least 4 consecutive weeks
Control Group Patients:
  • Age 18 or older
  • Diagnosed with active cancer meeting same criteria as above but without thrombosis

Principal Investigator

Scott Tagawa, MD

Contact

Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
roh2026@med.cornell.edu

Top of page